tiprankstipranks
Trending News
More News >
Suzuken Co (JP:9987)
:9987
Advertisement

Suzuken Co (9987) AI Stock Analysis

Compare
0 Followers

Top Page

JP:9987

Suzuken Co

(OTC:9987)

Rating:65Neutral
Price Target:
Suzuken Co's strong financial performance, highlighted by revenue growth and operational profitability, is the key strength. However, technical indicators suggest potential market underperformance, and cash flow volatility remains a concern. Valuation metrics indicate a fair price with reasonable income potential.

Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)

Suzuken Co Business Overview & Revenue Model

Company DescriptionSuzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
How the Company Makes MoneySuzuken Co. makes money through its core business of pharmaceutical distribution. The company generates revenue by purchasing pharmaceutical products from manufacturers and distributing them to a network of pharmacies, hospitals, and healthcare providers. It earns margins on the distribution of these products. Additionally, Suzuken may engage in partnerships with pharmaceutical companies for exclusive distribution agreements, which can enhance its revenue streams. The company also offers logistics and healthcare-related services, contributing to its income by providing comprehensive solutions to its clients in the healthcare sector.

Suzuken Co Financial Statement Overview

Summary
Suzuken Co demonstrates strong revenue growth and profitability with robust margins and a debt-free balance sheet, indicating solid financial health. However, cash flow volatility suggests a need for better liquidity management.
Income Statement
85
Very Positive
Suzuken Co showcases a strong financial performance with a consistent increase in revenue over the years, indicating healthy growth. The TTM data reveals a gross profit margin of 8.02% and an impressive net profit margin of 1.42%. EBIT and EBITDA margins are also robust at 1.58% and 2.00% respectively, illustrating efficient cost management and operational profitability.
Balance Sheet
80
Positive
The balance sheet reflects solid financial health with zero debt, highlighting the company's strong financial position. The equity ratio stands at 31.72%, indicating a stable capital structure. The return on equity (ROE) is 8.27%, reflecting satisfactory shareholder returns, though there is room for improvement in increasing equity utilization.
Cash Flow
70
Positive
Cash flow analysis shows volatility, as demonstrated by fluctuations in free cash flow over the years. While operating cash flows have been positive, the TTM data indicates a lack of reported cash flow figures, which poses challenges in assessing current cash position and sustainability. Historical data suggests the need for better cash management strategies.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue2.40T2.39T2.31T2.23T2.13T
Gross Profit192.23B185.25B179.69B160.99B157.84B
EBITDA62.38B51.40B39.48B32.55B22.92B
Net Income34.50B29.02B20.34B14.39B7.89B
Balance Sheet
Total Assets1.11T1.23T1.15T1.14T1.11T
Cash, Cash Equivalents and Short-Term Investments141.58B242.11B192.70B201.46B212.12B
Total Debt0.000.001.80B2.12B2.28B
Total Liabilities706.41B812.26B734.57B723.66B696.51B
Stockholders Equity407.29B416.31B411.21B417.69B417.05B
Cash Flow
Free Cash Flow-79.39B71.58B19.53B-4.77B7.74B
Operating Cash Flow-65.08B87.22B37.27B9.52B15.60B
Investing Cash Flow20.38B10.35B-46.36B1.44B-14.59B
Financing Cash Flow-35.48B-31.72B-26.22B-11.60B-7.39B

Suzuken Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5890.00
Price Trends
50DMA
5402.48
Positive
100DMA
5205.78
Positive
200DMA
4997.75
Positive
Market Momentum
MACD
147.97
Negative
RSI
79.79
Negative
STOCH
89.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Positive. The current price of 5890 is above the 20-day moving average (MA) of 5576.20, above the 50-day MA of 5402.48, and above the 200-day MA of 4997.75, indicating a bullish trend. The MACD of 147.97 indicates Negative momentum. The RSI at 79.79 is Negative, neither overbought nor oversold. The STOCH value of 89.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9987.

Suzuken Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥335.77B13.018.32%1.70%1.67%31.66%
51
Neutral
$7.39B0.36-62.86%2.36%15.48%-2.68%
$2.85B14.655.93%3.41%
$3.24B12.106.81%2.66%
76
Outperform
¥427.32B23.18
0.33%14.79%35.84%
70
Outperform
¥58.18B9.00
3.55%2.19%30.09%
68
Neutral
¥345.22B15.63
1.23%2.83%-2.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9987
Suzuken Co
5,890.00
806.08
15.86%
ARHCF
Alfresa Holdings
14.94
0.99
7.10%
MEPDF
Medipal Holdings
15.90
-0.39
-2.39%
JP:3151
Vital KSK Holdings, Inc.
1,267.00
139.11
12.33%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,195.00
1,222.30
41.12%
JP:8129
Toho Holdings Co., Ltd.
5,292.00
1,181.50
28.74%

Suzuken Co Corporate Events

Suzuken Co. Revises Financial Forecast Upward Amid Strong Sales
Apr 30, 2025

Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 10, 2025